A Study of TQA3526 in the Treatment of Primary Biliary Cirrhosis (PBC)

Summary

TQA3526 is a modified bile acid and FXR agonist. FXR is a key regulator of bile acid synthesis and transport. Bile acids are used by the body to help with digestion. It is hypothesized that regular treatment with TQA3526 will improve liver function in persons with Primary Biliary Cirrhosis (PBC).

Timeline

Start

2020-03-20

Primary completion

2022-11-30

Completion

2022-11-30

Drugs

Indications